LOGIN  |  REGISTER
Cue Biopharma
Assertio

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

March 28, 2024 | Last Trade: US$44.41 0.71 1.62

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.

Details of the planned presentations are listed below:

Revolution Medicines Oral Presentations:

Title:Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor
Presenter:John Knox, Ph.D.
Abstract Number:ND03
Session:New Drugs on the Horizon: Part 1
Date/Time:1:45 – 2:00 p.m. PT on April 7, 2024
  
Title: RMC-6236, a RAS(ON) Multi-Selective Tri-Complex Inhibitor
Presenter:Elena Koltun, Ph.D., Wei Lin, M.D. 
Session:KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology 
Date/Time: 1:00 – 1:20 p.m. PT on April 9, 2024 
  
Title:Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRASG12C NSCLC
Presenter:Xing Wei, Ph.D.
Abstract Number: 6585 
Session: Novel Antitumor Agents 5 
Date/Time:2:35 – 2:50 p.m. PT on April 9, 2024
  

Revolution Medicines Poster Presentations:

Title:Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC Models
Presenter:Lillian Seu, Ph.D. 
Abstract Number:581/4 
Session:Immunotherapy 
Date/Time:1:30 – 5:00 p.m. PT on April 7, 2024 
  
Title: RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRASG12V Xenograft Tumors
Presenter:Zhe Chen, M.B.B.S., Ph.D. 
Abstract Number:3340/28   
Session:Novel Antitumor Agents 3   
Date/Time: 1:30 – 5:00 p.m. PT on April 8, 2024
  
Title:The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRASG12X-Mutant Cancers
Presenter:Priyanka Bapat, Ph.D. 
Abstract Number: 4709/2 
Session: Other Cellular Mechanisms for Anticancer Drug Action 
Date/Time:9:00 a.m. – 12:30 p.m. PT on April 9, 2024 
  

Collaborator Poster Presentations:

Title:RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRASG12C Inhibitors in Preclinical Models
Lead RevMed Co-Author:Harshit Shah, Ph.D.
Abstract Number:1924/2
Session:Drug Resistance 2: RAS GTPase
Date/Time:9:00 a.m. – 12:30 p.m. PT on April 8, 2024
  
Title: Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS Effectors
Lead RevMed Co-Author:Jingjing Jiang, Ph.D. 
Abstract Number:1927/5 
Session:Drug Resistance 2: RAS GTPase 
Date/Time: 9:00 a.m. – 12:30 p.m. PT on April 8, 2024 
  

Additional information on the AACR Annual Meeting 2024 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2024/

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB